MT-3995 Low

DRUG4 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Diabetic Nephropathy

Phase 2

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

CompletedNCT01756716

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2012-12-31End: 2014-09-30Updated: 2015-02-09

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

CompletedNCT01756703

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2012-11-30End: 2014-08-31Updated: 2015-02-09

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

CompletedNCT02517320

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2015-07-31End: 2017-01-31Updated: 2017-03-03

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

CompletedNCT02676401

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2016-02-29Updated: 2017-09-18

Related Papers

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.

2020-09-2464 citations